Last update 21 Nov 2024

Cerdulatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-(cyclopropylamino)-2-((4-(4-(ethanesulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide, 5-pyrimidinecarboxamide, 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)-1-piperazinyl)phenyl)amino)-, Dual-SYK/JAK-inhibitor-Portola Pharmaceuticals
+ [6]
Target
Mechanism
JAK inhibitors(Janus kinase inhibitors), Syk inhibitors(Spleen tyrosine kinase inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2/3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC20H27N7O3S
InChIKeyBGLPECHZZQDNCD-UHFFFAOYSA-N
CAS Registry1198300-79-6

External Link

KEGGWikiATCDrug Bank
-Cerdulatinib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anaplastic Large-Cell LymphomaPhase 3-15 Nov 2019
Enteropathy-Associated T-Cell LymphomaPhase 3-15 Nov 2019
Follicular LymphomaPhase 3-15 Nov 2019
hepatosplenic T-cell lymphomaPhase 3-15 Nov 2019
Immunoblastic LymphadenopathyPhase 3-15 Nov 2019
Histiocytic SarcomaPhase 1-15 Nov 2019
Peripheral T-Cell LymphomaPhase 1-15 Nov 2019
T-cell lymphoma recurrentPhase 1-15 Nov 2019
T-Cell LymphomaPhase 1
US
30 Aug 2013
Follicular LymphomaDiscovery-15 Nov 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
40
(gduvefwwwm) = vpkunbefiz taabecnfqm (feviffamwm )
-
14 Jun 2019
(gduvefwwwm) = gtpteiwfpq taabecnfqm (feviffamwm )
Phase 2
-
(fdutctagua) = 22% iempjykvvr (titvklztln )
Positive
12 Jun 2019
Phase 1
43
vlkhzcmipq(mvsxhtqezf) = gsvfkifiux qehgmovkmm (aogamclkuh )
-
15 Feb 2019
Phase 2
18
(iafykebmfv) = 33% jbzckvvbaf (crisacrujy )
Positive
01 Jun 2018
Phase 1
41
lozfmkxuph(ykyssrlecb) = One DLT of pancreatitis was observed in the 45mg BID cohort and the cohort will now expand to 6 pts. xlqsxltasi (euvtsvsvkj )
Positive
20 May 2016
Phase 1/2
260
(fmxmlgleox) = qyoaemjcbj wlekfjfrrp (stjvmirpja )
-
20 May 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free